Overview
Portfolio
More
Diamondmedino
Fukuoka, Japan
Focus on developing robotic-assisted microsurgery technology to improve surgical outcomes and patient quality of life.
Portfolio
5+
Employees
<3
Founded
2021
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
United Kingdom
Fund details
Funds
DMC 1st Fund
Vintage 2022
Sources
Diamondmedino
Focus on developing robotic-assisted microsurgery technology to improve surgical outcomes and patient quality of life.
Portfolio
5+
Employees
<3
Founded
2021
AUM
N/A
Funds
DMC 1st Fund · Vintage 2022
Stages
No stages listed
Industries
No industries listedGeographic scope
United Kingdom
Sources
Showing 5 of 5 matched portfolio companies
FerroptoCure develops therapeutic drugs that utilize ferroptosis to create targeted anticancer therapies for patients with cancer. The company aims to provide effective treatment options based on scientific evidence, addressing the need for more effective cancer therapies.
The startup manufactures a robotic microsurgery assist system designed to enhance the precision of surgical tool handling during microsurgery procedures. This technology aims to reduce the physical and mental strain on surgeons while standardizing surgical practices, ultimately improving patient outcomes.
Funding: $3.9M
Rough estimate of the amount of funding raised
Funding: $3.9M
Rough estimate of the amount of funding raised
Global Vascular develops a drug-eluting stent delivery system utilizing nanotechnology to treat lower limb artery disease. This technology aims to improve blood flow and reduce the risk of thrombosis in patients suffering from ischaemia.
HUI is a cloud-based platform that centralizes business process management, integrating various functions to streamline operations. This reduces the complexity of handling multiple systems, leading to enhanced decision-making and more efficient resource allocation.
StapleBio develops nucleic acid medicines using its proprietary Staple nucleic acid technology, which selectively binds to target mRNA and alters its structure to modulate protein expression levels. This approach enables the rapid development of treatments for rare diseases, viral infections, and other conditions that have been difficult to address with traditional therapies.